NCT00946595View on ClinicalTrials.gov

Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

January 31, 2014

Conditions
HIV Infections
Interventions
DRUG

efavirenz/emtricitabin/tenofovir

1x600/200/245 mg per day (one tablet) between W0 et W98

DRUG

lopinavir/ritonavir

4 x 200/50 mg (4 tablets) once a day between W0 and W98

Trial Locations (1)

72012

Service des maladies infectieuses et tropicales Hopital Saint-Antoine, Paris

Sponsors

Collaborators (2)

Abbott
Gilead Sciences
All Listed Sponsors
collaborator

Abbott

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00946595 - Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients | Biotech Hunter | Biotech Hunter